Tengion to Present at Leerink Swann Novel Biologics Therapeutics Roundtable Conference

EAST NORRITON, Pa., Jan. 17 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that Steven Nichtberger, M.D., President and Chief Executive Officer, will be presenting at the Leerink Swann Novel Biologics Therapeutics Roundtable Conference on Thursday, January 24, 2008 at 10:15 AM Eastern Time. Tengion also will participate in the conference's panel discussions with members of Leerink Swann's MEDACorp Clinical Opinion Leaders. The conference will be held at Le Parker Meridien Hotel in New York City.

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure -- rather than treat -- organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.

SOURCE Tengion Inc.

Suggested Articles

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.

The deal, which is worth up to $160 million per molecule in milestones, comes as Junshi tries to pull off a $684 million IPO.